Ambroxol Hydrochloride

Introduction Overview

Generic Name

Brand Name

Various (not specified)

Dosage Form

Tablets (30 mg), Syrup (15 mg/5 mL)

Drug Class

Mucolytic agent, Expectorant

Pharmacokinetics

Absorption

Ambroxol is well absorbed from the gastrointestinal tract following oral administration, with onset of action approximately 30 minutes post-dose. The bioavailability is moderate due to some first-pass metabolism, and peak plasma concentrations are typically reached within 1 to 2 hours. Food intake does not significantly affect its absorption, making the therapeutic effect consistent regardless of meals.

Distribution

After absorption, ambroxol is widely distributed throughout the body tissues, with particularly high concentrations in the respiratory tract, including bronchial secretions and lung tissue, which is the target site for its mucolytic activity. It exhibits a moderate volume of distribution and is capable of crossing biological membranes to exert effects locally at the respiratory mucosa.

Metabolism

Ambroxol undergoes extensive hepatic metabolism primarily through conjugation pathways, including glucuronidation and sulfation. Less than 10% of the dose is excreted unchanged. The metabolic process results in inactive metabolites which do not contribute to pharmacological activity.

Elimination

Elimination occurs mainly via renal excretion of ambroxol metabolites. The half-life is approximately 10 hours, allowing for administration two to three times daily. Renal clearance supports sustained drug levels in plasma and respiratory tissues with regular dosing.

Dosage Forms

Adults

Ambroxol tablets are typically administered in doses ranging from 30 mg once daily up to 120 mg daily, divided into two or three doses depending on severity and response. Syrup formulations are also used for ease of dosing, particularly when swallowing tablets is difficult.

Adolescents

Dosing in adolescents is generally similar to adults, with oral tablets or syrup used according to weight and symptomatology, maintaining the same per-dose and daily quantities adapted for patient tolerance.

Special Populations

In young children, syrup formulations are preferred for ease of dosing: for children up to 2 years, half a teaspoonful twice daily; for ages 2 to 5 years, half a teaspoonful three times daily; over 5 years, one teaspoonful two to three times daily. Caution is advised in patients with gastric ulceration due to the drug’s mucolytic and local anesthetic action. Use in pregnancy is generally avoided in the first trimester due to limited safety data.

Mechanism Of Action

Ambroxol acts primarily as a mucolytic agent by stimulating the production and release of surfactant from type II pneumocytes in the lungs, which reduces the viscosity and adhesiveness of mucus, facilitating its clearance through mucociliary transport. This surfactant activity also protects epithelial cells and improves mucus clearance efficiency.

At the molecular level, ambroxol promotes the breakdown of acid mucopolysaccharide fibers in the sputum, thinning the mucus and allowing easier expectoration. Its ability to stimulate lysosomal enzymes enhances the hydrolysis of mucus components, improving sputum rheology.

Additionally, ambroxol exhibits a local anesthetic effect by blocking voltage-dependent sodium channels in sensory neurons of the respiratory tract mucosa, which contributes to symptomatic relief of sore throat and cough by reducing irritation and cough reflex sensitivity.

Unlike other mucolytics such as N-acetylcysteine which break disulfide bonds in mucus glycoproteins, ambroxol’s mechanism emphasizes surfactant stimulation and enzymatic breakdown, providing a complementary mucokinetic and mucoregulatory action supported by clinical studies.

Pharmacological Actions

Thinning and reducing viscosity of bronchial mucus to facilitate expectoration
Stimulation of pulmonary surfactant production by type II pneumocytes
Enhancement of mucociliary clearance in the respiratory tract
Local anesthetic and antitussive effects reducing sore throat pain and cough reflex
Promotion of lysosomal enzyme activity improving mucus degradation
Anti-inflammatory properties reducing bronchial mucosal irritation
Support in the resolution of bronchial secretions during respiratory infections
Improvement in lung tissue regeneration and repair processes

Therapeutic Clinical Uses

Treatment of acute and chronic respiratory diseases with excessive or thick mucus such as tracheobronchitis
Management of bronchitis associated with COPD or emphysema
Adjunct therapy in bronchiectasis to aid sputum clearance
Relief of congestion in pneumoconiosis and chronic inflammatory pulmonary conditions
Use in bronchospasm asthma with mucus hypersecretion
Supportive treatment during acute exacerbations of bronchitis alongside antibiotics
Symptomatic relief of sore throat via local anesthetic effects
Facilitation of sputum expectoration in various pulmonary infections

Side Or Adverse Effects

Mild gastrointestinal disturbances such as nausea or abdominal discomfort
Rare occurrences of diarrhea or dyspepsia
Occasional allergic reactions including rash or urticaria
Transient headache or dizziness in some patients
Local irritation or dryness in the mouth and throat with syrup use
Very rare reports of hypersensitivity reactions
No significant sedation or CNS depression reported
Generally well tolerated with mild side effect profile

Precautions

Use with caution in patients with active gastric or duodenal ulcer due to possible mucosal irritation
Avoid use during the first trimester of pregnancy unless clearly necessary
Monitor for hypersensitivity reactions especially in patients with asthma or allergy history
Caution advised in severe renal or hepatic impairment as pharmacokinetics may be altered
Avoid concurrent use with other expectorants without medical advice
Patients should maintain adequate hydration to aid mucolytic effects
Consider dose adjustment or discontinuation if gastrointestinal symptoms worsen
Not recommended for self-medication beyond short-term symptom relief

Warnings

Not absolute contraindications but caution is warranted in patients with gastric ulceration
Potential for hypersensitivity which may require immediate discontinuation
Storage at controlled temperature below 30°C to maintain drug stability
Keep out of reach of children to prevent accidental overdose
Patient monitoring advised during concomitant antibiotic use in bronchitis exacerbations
Not intended as sole therapy in severe respiratory infections without physician guidance
Avoid use if signs of severe rash or allergic reactions occur
Use under medical supervision in patients with pre-existing respiratory insufficiency

Contraindications

Known hypersensitivity to ambroxol hydrochloride or any excipients in the formulation
Relative contraindication in patients with gastric or duodenal ulceration due to local mucosal effects
Not recommended during the first trimester of pregnancy unless benefit outweighs risk
Severe hepatic or renal insufficiency without specialist advice
Children below 2 years without pediatric dosing supervision

Drug Interactions

No significant drug-drug interactions reported; however, caution with concomitant expectorants or mucolytics to avoid additive effects
Ambroxol may potentiate the effects of local anesthetics and other drugs affecting sodium channels
Use alongside antibiotics may improve sputum clearance but requires medical supervision
No known interactions with commonly used inhaled corticosteroids or bronchodilators
Monitor effects when used with agents that may cause gastrointestinal irritation
Limited data on interactions with CYP450 substrates, but metabolism is mainly via conjugation pathways
No significant interactions with anticoagulants or cardiovascular drugs reported

Preparations Of The Drug

Tablets containing 30 mg ambroxol hydrochloride per tablet
Oral syrup formulations with 15 mg ambroxol hydrochloride per 5 mL dose
Tablets are commonly packaged in boxes of 10 or 1000 units
Syrup available in bottles of 60 mL and 120 mL volumes
Formulations designed for adult and pediatric use with concentration adjustments
Commercial presentations intended for oral administration only
Pharmaceutical grade suitable for prescription and over-the-counter use in some countries